Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

Howard A. "Skip" Burris, MD
Published: Saturday, Dec 10, 2016



Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

<<< View more from the 2016 San Antonio Breast Cancer Symposium



Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

<<< View more from the 2016 San Antonio Breast Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x